Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Telaprevir ILLUMINATE Study May Light The Way To Shortened Hep C Treatment Time

This article was originally published in The Pink Sheet Daily

Executive Summary

Vertex released solid top-line data from a second Phase III study supporting a response-guided regimen that could halve the current 48-week standard course for many patients.

You may also be interested in...



Vertex, Merck Face Education Challenge With Complex Hep C Regimens

With two direct acting antivirals now pending at FDA, the hepatitis C community is excited about adding efficacious new drugs to standard of care. But the regimens aren't as simple as that sounds; once the therapies are approved, the sponsors will have a considerable education effort on their hands, as physicians and patients work their way through the new HCV treatment calculus.

Vertex, Merck Face Education Challenge With Complex Hep C Regimens

With two direct acting antivirals now pending at FDA, the hepatitis C community is excited about adding efficacious new drugs to standard of care. But the regimens aren't as simple as that sounds; once the therapies are approved, the sponsors will have a considerable education effort on their hands, as physicians and patients work their way through the new HCV treatment calculus.

Telaprevir’s Hidden Talents: New Data Show Effectiveness In Difficult To Cure Populations

Groups with historically poor responses to standard hepatitis C therapy made good progress when the direct-acting antiviral telaprevir was added to their regimen, Vertex Pharmaceuticals Inc. reported at the American Association for the Study of Liver Diseases Meeting in Boston.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel